Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-04-01 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
关于审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee regarding the performance and supervision of the external accounting firm (中汇会计师事务所) for the 2023 fiscal year audit. It details the committee's evaluation of the auditor's qualifications, independence, and audit process oversight. The document does not contain the audit report itself or financial statements but is a supervisory report on the auditor's work and compliance with regulatory requirements. The document length is short (1474 characters) and focuses on the audit committee's oversight rather than the audit report or annual report. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and supervisory information about audit firms, excluding full annual reports. FY 2023
2024-04-01 Chinese
2023年度审计报告
Regulatory Filings
2024-04-01 Chinese
关于拟注销两家三级子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed cancellation (注销) of two subsidiary companies by 江西新赣江药业股份有限公司. It includes details about the subsidiaries, the board meeting resolution approving the cancellation, and the impact on the company. There is no financial data, no mention of annual or interim reports, no audit information, no voting results, and no regulatory certifications. The document is a corporate announcement about management decisions related to subsidiaries, which fits best under general regulatory announcements or compliance disclosures. Given the nature and length of the document, it does not qualify as a full report but rather a regulatory announcement about corporate structure changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-04-01 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司为全资子公司提供担保的核查意见
Regulatory Filings
2024-03-20 Chinese
为全资子公司提供担保
Regulatory Filings Classification · 95% confidence The document is an official announcement by Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding the provision of a guarantee for its wholly-owned subsidiary. It details the guarantee amount, the decision-making process, the relationship between the parties, and the impact on the company. The document includes meeting resolutions and opinions from the board and the sponsoring institution. It does not contain financial statements or detailed financial performance data but is a disclosure about a specific corporate action (providing a guarantee). The document length is 3017 characters, which is relatively short and focused on a specific event rather than a comprehensive report. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about a corporate guarantee and related compliance information, not a full financial report or other specific filing type.
2024-03-20 Chinese
第二届董事会第二十八次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 28th meeting of the 2nd Board of Directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and related procedural compliance. The content focuses on board decisions, specifically about providing guarantees for a subsidiary, and includes references to related documents and opinions. There is no financial report, earnings data, or regulatory filing beyond the board meeting resolution. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-03-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.